Epithelial Cell Maturity Analysis for Bacterial Vaginosis Staging

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing bacterial vaginosis (BV) do not effectively distinguish between stages of the condition, leading to inadequate treatment and increased susceptibility to infections, as they rely on subjective symptoms and do not account for the stage of BV, which is crucial for determining the risk of infection and appropriate treatment.

Innovation Solution

A method involving the analysis of cervicovaginal smears to determine the number and maturity of shed epithelial cells, allowing for the differentiation between Stage I and Stage II BV, which involves obtaining a vaginal secretion sample, counting total and mature epithelial cells, and using specific log10 cell count ranges to diagnose the stages.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If Amsel's criteria are used for diagnosing BV, then the diagnosis can be made based on simple clinical signs, but the stage of BV cannot be determined and symptomatic vs asymptomatic BV cannot be distinguished

Engineering Contradiction:

Improvediagnosis simplicityVSAvoidstage information

Core Design Contradiction:

Ease of operationVSLoss of information

Solution Approach 1:

The patent segments the BV condition into distinct stages (Stage I and Stage II) based on epithelial cell maturity patterns. By dividing the diagnostic approach into specific cell count thresholds and maturity assessments, the method enables stage differentiation while maintaining clinical feasibility through standardized counting protocols

Inventive Principle:

Principle #1Segmentation

2Measurement precision

If Nugent scoring is used to diagnose BV, then microbiota composition can be assessed, but the stage of BV and distinction between symptomatic and asymptomatic cases cannot be determined

Engineering Contradiction:

Improvemicrobiota assessmentVSAvoidstage differentiation

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent introduces epithelial cell maturity assessment as an intermediary diagnostic parameter that bridges microbiota composition analysis and clinical stage determination. By using cell maturity patterns as a mediator, the method translates microbiota changes into clinically actionable stage information without requiring separate testing

Inventive Principle:

Principle #24Intermediary (Mediator)

3Device complexity

If no staging system is used, then treatment can be simplified, but treatment appropriateness is compromised due to inability to identify high-risk Stage II BV cases

Engineering Contradiction:

Improvetreatment protocolVSAvoidtreatment appropriateness

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent applies local quality by differentiating treatment approaches based on localized cell maturity patterns in specific regions of the vaginal epithelium. By assessing maturity at different epithelial levels (superficial vs intermediate cells), the method identifies Stage II BV with localized cellular changes that warrant targeted intervention

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20220357309A1Methods for distinguishing the stages of bacterial vaginosis

Publication Date: 2022.11.10 UNIV OF MARYLAND

AI summary

This application provides a method for staging bacterial vaginosis (BV), i.e., determining whether a subject does not have BV, has Stage I BV, or has Stage II BV. The method relies on testing for the number and maturity of shed epithelial cells from a sample of vaginal secretion from the subject. Specific diagnosis of Stage I or Stage II BV allows the clinician to provide a targeted and appropriate treatment or treatment course for the subject.